Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2880)	6/2/2010 4:52:48 PM
From: Jibacoa	1 Recommendation Respond to of 3722

DARAD was up 14.44% at its intraday H at 1:50pm but it closed up only 12.53% and it isn't doing well AHs.<g> The stock seems to have found support at the $3.60 level and was able to close above $4 during the regular session. bigcharts.marketwatch.com DARAD has been trimming its losses in the last 4Qs and the EL for 2010 is around $0,60 vs. a loss of $2.98 in 2008 and $6.72 in 2008 For 2011 expectations are for it to report on the black around $0.05 <g> It announced yesterday that on May 28 it had received a notice from the NAZ that it was back in compliance with the requirements for continued listing.<g> DARAD has two drug candidates in development,including KRN5500, which completed a PIIa for the treatment of neuropathic pain in patients with cancer and DB959 for the treatment of metabolic diseases, including type 2 D.M. The ACTAY is $14 DARAD has been burning cash for many years.<g> I will just keep a target of $6 for a possible 50^ gain from present levels. But DARAD seems to have plenty of room to run upstairs .<G> bigcharts.marketwatch.com Bernard